24 Oct 2026, 06:29 IST
Dr. Reddy's Laboratories Limited
HDFC Securities · REDUCE · target INR 1,270
The report says Dr Reddy's EBITDA declined 27% YoY on a 3% sales decline driven by a 30% YoY US decline, with TP revised to INR 1,270 and REDUCE rating retained.
From HSIE Results Daily 24 Oct 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.